pioglitazone has been researched along with Vitiligo in 1 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Vitiligo: A disorder consisting of areas of macular depigmentation, commonly on extensor aspects of extremities, on the face or neck, and in skin folds. Age of onset is often in young adulthood and the condition tends to progress gradually with lesions enlarging and extending until a quiescent state is reached.
Excerpt | Relevance | Reference |
---|---|---|
"Vitiligo is a complex disease wherein derangements in multiple pathways determine the loss of functional melanocytes." | 1.72 | A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist. ( Bellei, B; Caputo, S; Cigliana, G; D'Arino, A; Iacovelli, P; Migliano, E; Ottaviani, M; Pacifico, A; Papaccio, F; Picardo, M; Sciuto, L; Truglio, M, 2022) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Papaccio, F | 3 |
Bellei, B | 3 |
Ottaviani, M | 3 |
D'Arino, A | 3 |
Truglio, M | 3 |
Caputo, S | 3 |
Cigliana, G | 3 |
Sciuto, L | 3 |
Migliano, E | 3 |
Pacifico, A | 3 |
Iacovelli, P | 3 |
Picardo, M | 3 |
1 other study available for pioglitazone and Vitiligo
Article | Year |
---|---|
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |
A Possible Modulator of Vitiligo Metabolic Impairment: Rethinking a PPARγ Agonist.
Topics: Humans; Hypoglycemic Agents; Melanocytes; Pioglitazone; PPAR gamma; Vitiligo | 2022 |